STAT5 is also involved in breast tumorigenesis and Janus kinase 1 (JAK1) activation via the prolactin receptor, whereas JAK2 activity has been shown to enhance STAT5 signaling in breast cancer cells [11]. This evidence concerns the gene JAK1 and breast carcinoma.